SubHero Banner

Sunlenca® (lenacapavir) – New drug approval

December 22, 2022 - The FDA announced the approval of Gilead Sciences’ Sunlenca (lenacapavir), in combination with other antiretroviral(s), for the treatment of human immunodeficiency virus (HIV)-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations.

Download PDF